|
2025-06-16 |
2025-06-13 |
PS
Planned sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
1,000
-2.3%
28.43
USD 51,909
|
1,000
-2.3%
|
28.43
|
USD 100,000
|
|
|
2025-06-16 |
2025-06-13 |
PS
Planned sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
1,000
-15.0%
28.42
USD 406,601
|
1,000
-15.0%
|
28.42
|
USD 100,000
|
|
|
2025-06-16 |
2025-06-13 |
PS
Planned sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
1,000
-1.3%
28.47
USD 35,669
|
1,000
-1.3%
|
28.47
|
USD 100,000
|
|
|
2025-06-16 |
2025-06-13 |
PS
Planned sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
1,000
-8.3%
28.46
USD 248,953
|
1,000
-8.3%
|
28.46
|
USD 100,000
|
|
|
2025-05-27 |
2025-05-27 |
S
Sale
|
Holloway Jean F
SVP, General Counsel
Officer
|
8,748
-4.7%
29.00
USD 253,692
|
8,748
-4.7%
|
29.00
|
USD 253,692
|
|
|
2025-05-27 |
2025-05-23 |
S
Sale
|
SEMEDO ANTHONY B.
Non-Executive Director
|
2,600
-7.3%
28.47
USD 74,027
|
2,600
-7.3%
|
28.47
|
USD 74,027
|
|
|
2025-05-21 |
2025-05-21 |
S
Sale
|
Holloway Jean F
SVP, General Counsel
Officer
|
9,926
-5.0%
29.00
USD 287,854
|
9,926
-5.0%
|
29.00
|
USD 287,854
|
|
|
2025-05-12 |
2025-05-09 |
S
Sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
4,811
-4.4%
29.13
USD 140,145
|
4,811
-4.4%
|
29.13
|
USD 140,145
|
|
|
2025-05-12 |
2025-05-09 |
S
Sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
5,737
-5.0%
29.13
USD 167,120
|
5,737
-5.0%
|
29.13
|
USD 167,120
|
|
|
2025-03-12 |
2025-03-11 |
PS
Planned sale
|
Holloway Jean F
SVP, General Counsel
Officer
|
18,020
-8.4%
23.61
USD 425,510
|
18,020
-8.4%
|
23.61
|
USD 425,510
|
|
|
2025-03-12 |
2025-03-11 |
PS
Planned sale
|
Davis John E
Chief Commercial Officer
Officer
|
15,100
-6.7%
23.61
USD 356,549
|
15,100
-6.7%
|
23.61
|
USD 356,549
|
|
|
2025-03-10 |
2025-03-06 |
S
Sale
|
Horton Amy
VP, Chief Accounting Officer
Officer
|
1,048
-0.7%
24.80
USD 25,995
|
1,048
-0.7%
|
24.80
|
USD 25,995
|
|
|
2025-03-10 |
2025-03-06 |
PS
Planned sale
|
Mackin James P
President & CEO
Officer
|
70,700
-7.6%
24.76
USD 1,750,843
|
70,700
-7.6%
|
24.76
|
USD 1,750,843
|
|
|
2025-03-10 |
2025-03-06 |
S
Sale
|
Mackin James P
President & CEO
Officer
|
17,739
-2.0%
24.80
USD 440,005
|
17,739
-2.0%
|
24.80
|
USD 440,005
|
|
|
2025-03-10 |
2025-03-06 |
S
Sale
|
Holloway Jean F
SVP, General Counsel
Officer
|
2,124
-1.1%
24.80
USD 52,685
|
2,124
-1.1%
|
24.80
|
USD 52,685
|
|
|
2025-03-10 |
2025-03-06 |
S
Sale
|
Davis John E
Chief Commercial Officer
Officer
|
2,618
-1.2%
24.80
USD 64,939
|
2,618
-1.2%
|
24.80
|
USD 64,939
|
|
|
2025-03-10 |
2025-03-06 |
S
Sale
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Officer
|
1,603
-1.4%
24.80
USD 39,761
|
1,603
-1.4%
|
24.80
|
USD 39,761
|
|
|
2025-03-10 |
2025-03-06 |
S
Sale
|
Berry Lance A
Executive VP, CFO
Officer
|
4,909
-3.1%
24.80
USD 121,764
|
4,909
-3.1%
|
24.80
|
USD 121,764
|
|
|
2025-03-06 |
2025-03-05 |
S
Sale
|
Holloway Jean F
SVP, General Counsel
Officer
|
472
-0.3%
25.29
USD 11,935
|
472
-0.3%
|
25.29
|
USD 11,935
|
|
|
2025-03-05 |
2025-03-05 |
B
Purchase
|
SEMEDO ANTHONY B.
Non-Executive Director
|
600
+inf%
25.25
USD 15,150
|
600
+inf%
|
25.25
|
USD 15,150
|
|
